Titus Ball Sells 169 Shares of BeOne Medicines (NASDAQ:ONC) Stock

Posted by Brenda Bartman on Jun 17th, 2026

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) insider Titus Ball sold 169 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $257.20, for a total value of $43,466.80. Following the sale, the insider owned 99,645 shares in the company, valued at $25,628,694. The trade was a 0.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Price Performance

Shares of ONC opened at $263.92 on Wednesday. BeOne Medicines Ltd. – Sponsored ADR has a 52 week low of $239.25 and a 52 week high of $385.22. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The firm has a market cap of $28.96 billion, a price-to-earnings ratio of 59.04 and a beta of 0.49. The stock has a 50 day moving average of $297.63 and a 200-day moving average of $313.49.

BeOne Medicines (NASDAQ:ONC – Get Free Report) last posted its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. The business had revenue of $1.51 billion for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. As a group, analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current year.

Institutional Trading of BeOne Medicines

Several large investors have recently added to or reduced their stakes in the business. EFG International AG bought a new stake in BeOne Medicines during the 4th quarter valued at $25,000. Leonteq Securities AG bought a new position in shares of BeOne Medicines in the fourth quarter worth $35,000. Daiwa Securities Group Inc. bought a new position in shares of BeOne Medicines in the second quarter worth $35,000. CWM LLC increased its holdings in shares of BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after purchasing an additional 39 shares during the period. Finally, Group One Trading LLC bought a new stake in shares of BeOne Medicines during the fourth quarter valued at about $61,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently weighed in on ONC. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. Wolfe Research began coverage on BeOne Medicines in a research note on Friday, March 27th. They issued an “outperform” rating and a $340.00 target price for the company. Guggenheim upped their target price on BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Morgan Stanley reiterated an “overweight” rating and set a $395.00 price target on shares of BeOne Medicines in a research report on Thursday, May 7th. Finally, Wells Fargo & Company initiated coverage on BeOne Medicines in a report on Monday, May 4th. They issued an “overweight” rating and a $400.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $390.00.

Check Out Our Latest Report on BeOne Medicines

BeOne Medicines Company Profile

(Get Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.